-
11.发明授权
公开(公告)号：EP3003181B1
公开(公告)日：2018-02-21
申请号：EP14807718.3
申请日：2014-06-03
Applicant: Faculty Physicians and Surgeons of Loma Linda University School of Medicine , Loma Linda University
Inventor： BALDWIN, Dalton Duane , YEO, Alexander , MARTIN, Jacob
IPC: A61B17/34 , A61M25/01 , A61M25/095 , A61M25/10 , A61B90/13
CPC classification number: A61B17/3415 , A61B1/00147 , A61B1/00154 , A61B1/018 , A61B1/063 , A61B1/0676 , A61B1/307 , A61B5/061 , A61B5/065 , A61B6/12 , A61B6/485 , A61B6/487 , A61B8/0841 , A61B17/00234 , A61B17/3403 , A61B17/3423 , A61B34/20 , A61B90/13 , A61B2017/0034 , A61B2017/00707 , A61B2017/00853 , A61B2017/00907 , A61B2017/3413 , A61B2034/2055 , A61B2090/0807 , A61B2090/3762 , A61B2090/3966 , A61M25/0074 , A61M25/0097 , A61M25/10
Abstract: A needle access assembly and method for obtaining percutaneous needle access with little or no fluoroscopy. The method can include selecting a target for percutaneous access, directing a laser guide at a desired needle-insertion angle and in line with the selected target, aligning the needle access assembly with the laser, and inserting the needle into the target.
-
公开(公告)号：WO2019241479A1
公开(公告)日：2019-12-19
申请号：PCT/US2019/036912
申请日：2019-06-13
Applicant: LOMA LINDA UNIVERSITY , LOMA LINDA UNIVERSITY MEDICAL CENTER , FACULTY PHYSICIANS AND SURGEONS OF LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE
Inventor： CAO, Huynh , XU, Yi , PAYNE, Kimberly , BAYLINK, David
IPC: A61K31/593 , A61K35/28 , C12P19/34 , C12Q1/34
Abstract: In one aspect, engineered hematopoietic stem cells comprising a heterologous expression cassette are provided. In some embodiments, the expression cassette comprises a promoter operably linked to a polynucleotide that encodes a 1α-hydroxylase protein, wherein the 1α-hydroxylase protein is human cytochrome P450 family 27 subfamily B member 1 (CYP27B1).
-
13.发明授权Composition, preparation, and use of chitosan shards for biomedical applications 有权用于生物医学应用的壳聚糖碎片的组成，制备和使用公开(公告)号：US09414967B2
公开(公告)日：2016-08-16
申请号：US14991331
申请日：2016-01-08
Applicant: Loma Linda University , Loma Linda University Medical Center , North Carolina State University
Inventor： Wolff M. Kirsch , Samuel M. Hudson , Andrew Crofton
CPC classification number: A61F13/00987 , A61F13/00012 , A61F2013/00106 , A61K9/70 , A61K47/36 , A61L2/0035 , A61L2/081 , A61L24/0015 , A61L24/0042 , A61L24/08 , A61L2300/232 , A61L2300/404 , A61L2400/04 , A61L2400/18 , B29C43/003 , B29C2043/561 , B29C2793/009 , B29K2005/00 , B29L2031/7722 , C08L5/08
Abstract: A thin chitosan-based material can be used for biomedical applications. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan material. A single or multiple such treatments may be employed. For example, the chitosan material may be irradiated under nitrogen using γ-irradiation, treated under a nitrogen plasma, or both. A thin chitosan material can be readily treated by surface modifying treatments such as irradiating under nitrogen using γ-irradiation, treating under a nitrogen plasma, or both.
Abstract translation: 薄壳聚糖基材料可用于生物医学应用。 壳聚糖已经在氮气田中通过施加能量来电离壳聚糖材料中和周围的氮而被处理。 可以使用单次或多次这样的治疗。 例如，可以使用γ-照射在氮气下照射壳聚糖材料，在氮等离子体下进行处理，或者两者。 通过表面改性处理可以容易地处理薄壳聚糖材料，例如使用γ照射在氮气下照射，在氮等离子体下处理，或两者均可。
-
14.发明申请COMPOSITION, PREPARATION, AND USE OF CHITOSAN POWDER FOR BIOMEDICAL APPLICATIONS 审中-公开组合物，制备和使用生物医学应用的CHITOSAN粉末公开(公告)号：US20160082037A1
公开(公告)日：2016-03-24
申请号：US14863270
申请日：2015-09-23
Applicant: LOMA LINDA UNIVERSITY MEDICAL CENTER , North Carolina State University , LOMA LINDA UNIVERSITY
Inventor： Wolff M. Kirsch , Samuel M. Hudson , Andrew Crofton
IPC: A61K31/722 , A61L2/14 , A61L2/08
CPC classification number: A61K31/722 , A61K9/70 , A61L2/081 , A61L2/14
Abstract: A powder chitosan-based material can be used for biomedical applications. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan material. A single or multiple such treatments may be employed. For example, the chitosan material may be irradiated under nitrogen using γ-irradiation, treated under a nitrogen plasma, or both. A powder chitosan material can be readily treated by surface modifying treatments such as irradiating under nitrogen using γ-irradiation, treating under a nitrogen plasma, or both.
Abstract translation: 基于壳聚糖的粉末材料可用于生物医学应用。 壳聚糖已经在氮气田中通过施加能量来电离壳聚糖材料中和周围的氮而被处理。 可以使用单次或多次这样的治疗。 例如，可以使用γ-照射在氮气下照射壳聚糖材料，在氮等离子体下进行处理，或者两者。 粉末壳聚糖材料可以通过表面改性处理容易地进行处理，例如使用γ照射在氮气下照射，在氮等离子体下处理或两者。
-
公开(公告)号：US20150335912A1
公开(公告)日：2015-11-26
申请号：US14716781
申请日：2015-05-19
Inventor： John H. Zhang , Paul Krafft , Devin McBride , William Rolland
IPC: A61N5/10
CPC classification number: A61N5/10
Abstract: Irradiation treatment can be used before, during, or after a surgical treatment or other injury to the brain to decrease or prevent subsequent injury. Injury to the brain during surgery can induce the infiltration of peripheral immune cells, including splenic immune cells, into the brain. The infiltration of immune cells can create acute elevations in brain edema and blood-brain barrier disruption thereby decreasing neurological recover and patient outcomes. Irradiation of peripheral immune cells, or the region of the body in which the cells are derived, can allow for inactivation of the cells and prevent infiltration into the surgical site, for example, the brain.
Abstract translation: 可以在外科手术治疗或其他对脑部的损伤之前，期间或之后使用照射治疗，以减少或防止随后的损伤。 手术期间对大脑的损伤可诱发外周免疫细胞（包括脾脏免疫细胞）侵入脑部。 免疫细胞的浸润会引起脑水肿和血脑屏障破裂的急剧升高，从而减少神经恢复和患者的预后。 外周免疫细胞或细胞衍生的身体的区域的照射可允许细胞失活，并防止渗入手术部位，例如脑部。
-
Patent Agency Ranking
16.发明申请SUBSTANCES AND METHODS FOR THE TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY RELATED CONDITIONS OR DISEASES 审中-公开治疗椎间盘突出症相关病症或疾病的物质及方法公开(公告)号：US20150353623A1
公开(公告)日：2015-12-10
申请号：US14677953
申请日：2015-04-02
Applicant: Loma Linda University , Loma Linda University Medical Center , University of California, Los Angeles , University of California, Irvine , North Carolina State University
Inventor： Wolff M. Kirsch , Andrew Crofton , Tanya Cupino , Charles Glabe , Samuel M. Hudson , Matthew Schrag , Harry V. Vinters , Matthew Zabel
IPC: C07K14/705 , A61K31/713 , A61K45/06 , A61K31/192 , C07K16/18
CPC classification number: C07K14/70596 , A61K9/0019 , A61K9/0043 , A61K9/5161 , A61K31/192 , A61K31/713 , A61K39/395 , A61K45/06 , C07K16/18 , C07K2317/55 , A61K2300/00
Abstract: A substance for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system; and a vehicle for transporting the inhibitor into the cerebrovasculature; where the inhibition by the inhibitor is sufficient to decrease the incidence of or to prevent the incidence of cytolysis of the smooth muscle cells. A method for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising: a) identifying a patient with a cerebral amyloid angiopathy related condition or disease; b) providing one or more than one substance that comprises an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system, c) administering one or more than one dose of the one or more than one substance to the patient.
Abstract translation: 一种用于治疗患有脑血管病变的脑淀粉样血管病相关病症或疾病的物质，其包含抑制补体系膜分子复合物形成的抑制剂; 以及用于将抑制剂输送到脑血管系统中的载体; 其中抑制剂的抑制足以降低平滑肌细胞的细胞溶解的发生率或防止其发生。 一种治疗患者脑淀粉样血管病相关病症或影响脑血管系统疾病的方法，包括：a）鉴定患有脑淀粉样血管病相关病症或疾病的患者; b）提供一种或多于一种物质，其包含抑制剂，所述抑制剂引起所述补体系统的膜侵袭复合物的形成的抑制，c）向所述患者施用一种或多于一种的所述一种或多种物质。
-
公开(公告)号：US20150272701A1
公开(公告)日：2015-10-01
申请号：US14678696
申请日：2015-04-03
Applicant: FACULTY PHYSICIANS AND SURGEONS OF LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE , LOMA LINDA UNIVERSITY
Inventor： Dalton Duane Baldwin , Alexander Yeo , Jacob Martin
CPC classification number: A61B17/3415 , A61B1/00147 , A61B1/00154 , A61B1/018 , A61B1/063 , A61B1/0676 , A61B1/307 , A61B5/061 , A61B5/065 , A61B6/12 , A61B6/485 , A61B6/487 , A61B8/0841 , A61B17/00234 , A61B17/3403 , A61B17/3423 , A61B34/20 , A61B90/13 , A61B2017/0034 , A61B2017/00707 , A61B2017/00853 , A61B2017/00907 , A61B2017/3413 , A61B2034/2055 , A61B2090/0807 , A61B2090/3762 , A61B2090/3966 , A61M25/0074 , A61M25/0097 , A61M25/10
Abstract: A needle access assembly and method for obtaining percutaneous needle access with little or no fluoroscopy. The method can include selecting a target for percutaneous access, directing a laser guide at a desired needle-insertion angle and in line with the selected target, aligning the needle access assembly with the laser, and inserting the needle into the target.
-
公开(公告)号：US20210177908A1
公开(公告)日：2021-06-17
申请号：US17256509
申请日：2019-06-28
Applicant: LOMA LINDA UNIVERSITY , FACULTY PHYSICIANS AND SURGEONS OF LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE , THE UNITE STATES OF AMERICA AS REPRESENTED BY UNTED STATES DEPARTMENT OF VETERANS AFFAIRS
Inventor： Zhang XIAOBING , David BAYLINK , Wanqui CHEN , Kin-Hing William LAU
Abstract: In one aspect, anabolic agent fusion proteins and compositions comprising anabolic agent fusion proteins are provided. In some embodiments, the anabolic agent fusion protein comprises a platelet derived growth factor (PDGF) or a fibroblast growth factor (FGF) and an Asp-Ser-Ser tripeptide (DSS) repeat sequence. In another aspect, methods of promoting bone growth and methods of treating a fracture using anabolic agent fusion proteins and compositions comprising anabolic agent fusion proteins are provided.
-
公开(公告)号：US20160184429A1
公开(公告)日：2016-06-30
申请号：US14910674
申请日：2014-08-07
Applicant: LOMA LINDA UNIVERSITY MEDICAL CENTER , LOMA LINDA UNIVERSITY , NORTH CAROLINA STATE UNIVERSITY
Inventor： Wolff M. Kirsch , Samuel M. Hudson , Andrew Crofton
CPC classification number: A61K41/0019 , A61K9/0019 , A61K9/0024 , A61K9/5161 , A61K38/208 , A61K47/36 , A61L2/0011 , A61L2/0035 , A61L2/08
Abstract: A chitosan material is treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan, and the chitosan material is formulated into a hydrogel which can be utilized as a drug delivery vehicle for medicaments or therapeutic agents to treat certain conditions, such as cancers.
Abstract translation: 通过施加能量以将脱乙酰壳多糖及其周围的氮离子化，将脱乙酰壳多糖材料配制成水凝胶，其可用作药物递送载体用于药物或治疗剂以治疗某些病症，例如 作为癌症。
-
公开(公告)号：US20160121021A1
公开(公告)日：2016-05-05
申请号：US14991331
申请日：2016-01-08
Applicant: Loma Linda University , Loma Linda University Medical Center , North Carolina State University
Inventor： Wolff M. Kirsch , Samuel M. Hudson , Andrew Crofton
CPC classification number: A61F13/00987 , A61F13/00012 , A61F2013/00106 , A61K9/70 , A61K47/36 , A61L2/0035 , A61L2/081 , A61L24/0015 , A61L24/0042 , A61L24/08 , A61L2300/232 , A61L2300/404 , A61L2400/04 , A61L2400/18 , B29C43/003 , B29C2043/561 , B29C2793/009 , B29K2005/00 , B29L2031/7722 , C08L5/08
Abstract: A thin chitosan-based material can be used for biomedical applications. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan material. A single or multiple such treatments may be employed. For example, the chitosan material may be irradiated under nitrogen using γ-irradiation, treated under a nitrogen plasma, or both. A thin chitosan material can be readily treated by surface modifying treatments such as irradiating under nitrogen using γ-irradiation, treating under a nitrogen plasma, or both.
-
-
-
-
-
-
-
-
-
Search Results
575
records
(took 0.03 seconds)
